009420.KS
Hanall Biopharma Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 53,900.00
−2.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 162.7B | 155.2B | 138.9B | 134.9B | 110.0B |
| Cost of Revenue | 77.9B | 76.1B | 65.6B | 59.9B | 48.0B |
| Gross Profit | 84.7B | 79.1B | 73.3B | 75.0B | 62.0B |
| Operating Expenses | |||||
| R&D Expense | 11.9B | 19.3B | 18.9B | 23.9B | 16.5B |
| SG&A Expense | 47.1B | 38.3B | 30.0B | 48.0B | 23.2B |
| General & Admin Expense | 1.8B | 2.4B | 2.4B | 2.5B | 2.3B |
| Selling & Marketing Expense | 39.4B | 35.8B | 27.5B | 23.2B | 20.9B |
| Other Expenses | 25.4B | 23.1B | 24.2B | (1.0K) | 19.4B |
| Total Operating Expenses | 80.8B | 80.7B | 73.1B | 72.0B | 59.1B |
| Cost and Expenses | 158.6B | 156.1B | 138.7B | 131.9B | 108.5B |
| Operating Income (EBIT) | 3.9B | (1.6B) | 230.5M | 3.1B | 1.5B |
| Non-Operating | |||||
| Interest Income | 457.7M | 263.1M | 490.3M | 1.2B | 1.4B |
| Interest Expense | 891.0M | 142.5M | 71.0M | 63.9M | 21.9M |
| Net Interest Income | (433.3M) | 120.6M | 419.3M | 1.2B | 1.4B |
| Other Non-Op Income/Expense | (31.7B) | (4.6B) | (260.7M) | 146.5M | 423.6M |
| Non-Operating Income (excl Interest) | 5.1B | — | 342.7M | 1.3B | (445.5M) |
| EBT (Pre-Tax Income) | (27.7B) | (6.2B) | (30.2M) | 3.2B | 1.9B |
| Income Tax Expense | (2.8B) | (621.6M) | 1.6B | (306.1M) | 1.7B |
| Bottom Line | |||||
| Net Income | (24.9B) | (5.6B) | (1.8B) | 3.5B | 251.5M |
| Earnings from Cont. Ops | (24.9B) | (5.6B) | (1.7B) | 3.5B | 251.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.9B) | (5.6B) | (1.8B) | 3.5B | 251.5M |
| Per Share | |||||
| Basic EPS | (₩482) | (₩112) | (₩36) | ₩69 | ₩5 |
| Diluted EPS | (₩482) | (₩112) | (₩36) | ₩69 | ₩5 |
| Revenue Per Share | ₩3,114 | ₩3,115 | ₩2,740 | ₩2,661 | ₩2,165 |
| Shares | |||||
| Basic Shares Outstanding | 52.2M | 49.8M | 50.7M | 50.7M | 50.8M |
| Diluted Shares Outstanding | 52.2M | 49.8M | 50.7M | 50.7M | 50.8M |
| Profitability Metrics | |||||
| EBITDA | (13.5B) | 1.9B | 3.4B | 6.6B | 5.0B |
| D&A | 3.3B | 3.6B | 3.1B | 3.2B | 3.1B |
| EBIT | (16.9B) | (1.6B) | 230.5M | 3.3B | 2.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026